Literature DB >> 27730274

[Progressive multifocal leukoencephalopathy].

C Warnke1, M P Wattjes2, O Adams3, H-P Hartung4, R Martin5, T Weber6, M Stangel7.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a disease of immunosuppressed patients caused by the JC polyomavirus (JCPyV). Due to the elevated risk in patients treated with natalizumab for multiple sclerosis (MS) and also treatment with other biologicals for different indications, the relevance of PML has increased in recent years. This article summarizes the published knowledge on the biology and pathogenesis of PML with a focus on the role of cerebrospinal fluid diagnostics in the work-up for PML and the current PML case definition. Current recommendations regarding risk management are discussed, as are possible therapies and prevention.

Entities:  

Keywords:  Cerebrospinal fluid; JC polyomavirus; Multiple sclerosis; Natalizumab; PML

Mesh：

Substances：

Year:  2016        PMID： 27730274     DOI： 10.1007/s00115-016-0225-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  35 in total

1.  Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient.

Authors:  A Balduzzi; G Lucchini; H H Hirsch; S Basso; M Cioni; A Rovelli; A Zincone; M Grimaldi; P Corti; S Bonanomi; A Biondi; F Locatelli; E Biagi; P Comoli
Journal:  Bone Marrow Transplant       Date:  2010-10-04       Impact factor: 5.483

2.  JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.

Authors:  Tom Van Loy; Kim Thys; Caroline Ryschkewitsch; Ole Lagatie; Maria C Monaco; Eugene O Major; Luc Tritsmans; Lieven J Stuyver
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.

Authors:  Clemens Warnke; Vsevolod Smolianov; Thomas Dehmel; Marcel Andrée; Hartmut Hengel; Fabian Zohren; Gabriele Arendt; Heinz Wiendl; Rainer Haas; Hans-Peter Hartung; Ortwin Adams; Bernd C Kieseier
Journal:  Mult Scler       Date:  2010-11-15       Impact factor: 6.312

4.  MRI pattern in asymptomatic natalizumab-associated PML.

Authors:  Mike P Wattjes; Anke Vennegoor; Martijn D Steenwijk; Marlieke de Vos; Joep Killestein; Bob W van Oosten; Jop Mostert; Dorine A Siepman; Wiebe Moll; Alex E L van Golde; Stephan T F M Frequin; Nancy D Richert; Frederik Barkhof
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-09-09       Impact factor: 10.154

5.  Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Authors:  Mike P Wattjes; Anke Vennegoor; Jop Mostert; Bob W van Oosten; Frederik Barkhof; Joep Killestein
Journal:  J Neurol       Date:  2014-04-06       Impact factor: 4.849

6.  Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Authors:  Luisa M Villar; Lucienne Costa-Frossard; Thomas Masterman; Oscar Fernandez; Xavier Montalban; Bonaventura Casanova; Guillermo Izquierdo; Francisco Coret; Hayrettin Tumani; Albert Saiz; Rafael Arroyo; Katharina Fink; Laura Leyva; Carmen Espejo; María Simó-Castelló; María I García-Sánchez; Florian Lauda; Sara Llufriú; Roberto Álvarez-Lafuente; Javier Olascoaga; Alvaro Prada; Agustín Oterino; Clara de Andrés; Mar Tintoré; Lluis Ramió-Torrentà; Eulalia Rodríguez-Martín; Carmen Picón; Manuel Comabella; Ester Quintana; Eduardo Agüera; Santiago Díaz; Ricardo Fernandez-Bolaños; Juan A García-Merino; Lamberto Landete; Manuel Menéndez-González; Laura Navarro; Domingo Pérez; Fernando Sánchez-López; Pedro J Serrano-Castro; Alberto Tuñón; Mercedes Espiño; Alfonso Muriel; Amit Bar-Or; José C Álvarez-Cermeño
Journal:  Ann Neurol       Date:  2015-01-30       Impact factor: 10.422

Review 7.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

8.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-12

Review 9.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

10.  Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML).

Authors:  Shamil R Sunyaev; Alexey Lugovskoy; Kenneth Simon; Leonid Gorelik
Journal:  PLoS Genet       Date:  2009-02-06       Impact factor: 5.917
View more
  1 in total

Review 1.  The Cerebrospinal Fluid in Multiple Sclerosis.

Authors:  Florian Deisenhammer; Henrik Zetterberg; Brit Fitzner; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.